DIASTOLIC FUNCTION IN MYOSIN-BINDING PROTEIN C FOUNDER MUTATION CARRIERS WITH AND WITHOUT CLINICAL EVIDENCE OF HYPERTROPHIC CARDIOMYOPATHY

Volume: 73, Issue: 9, Pages: 931
Published: Mar 11, 2019
Abstract
The MYBPC3 (Myosin-binding protein C) c.927-2A>G founder mutation accounts for >90% of sarcomeric hypertrophic cardiomyopathy (HCM) in Iceland, allowing unique opportunity to explore the relation between genotype and clinical phenotype. This study explores the burden of diastolic dysfunction in...
Paper Details
Title
DIASTOLIC FUNCTION IN MYOSIN-BINDING PROTEIN C FOUNDER MUTATION CARRIERS WITH AND WITHOUT CLINICAL EVIDENCE OF HYPERTROPHIC CARDIOMYOPATHY
Published Date
Mar 11, 2019
Volume
73
Issue
9
Pages
931
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.